Frontier Capital Management’s Pacific Biosciences PACB Stock Holding History

Frontier Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-977,464	Closed	-$7.07M	–	301
2019 Q1	$7.07M	Sell	977,464 -67,881	-6%	-$491K	0.05%	248
2018 Q4	$7.74M	Sell	1,045,345 -333,113	-24%	-$2.11M	0.06%	247
2018 Q3	$7.46M	Sell	1,378,458 -51,047	-4%	-$219K	0.05%	257
2018 Q2	$5.08M	Sell	1,429,505 -23,198	-2%	-$64.4K	0.04%	262
2018 Q1	$2.98M	Sell	1,452,703 -7,041	-0.5%	-$18.3K	0.02%	269
2017 Q4	$3.85M	Sell	1,459,744 -28,287	-2%	-$99K	0.03%	270
2017 Q3	$7.81M	Sell	1,488,031 -18,503	-1%	-$79.5K	0.06%	247
2017 Q2	$5.36M	Buy	+1,506,534	New	+$6.07M	0.04%	269

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Frontier Capital Management's PACB Position: Q2 2019 in Review

Frontier Capital Management sold out of Pacific Biosciences (PACB) in Q2 2019, closing a stake of 977,464 shares — an estimated $7.07M sold.

Frontier Capital Management first reported a position in PACB in Q2 2017 and held it in 8 quarters. The position peaked at $7.81M in Q3 2017. 150 funds tracked by Wall St. Rank hold PACB as of Q2 2019.

Frontier Capital Management reported no remaining Pacific Biosciences position as of Q2 2019 after selling out during the quarter.
Frontier Capital Management sold 977,464 Pacific Biosciences shares in Q2 2019, an estimated $7.07M.
Frontier Capital Management first reported a position in Pacific Biosciences in Q2 2017 and held it in 8 quarters.
Frontier Capital Management's Pacific Biosciences position peaked at $7.81M in Q3 2017.
150 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2019.

Based on Frontier Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.